Health Promotion and Human Behavior : Kyoto University / 京都大学大学院 医学研究科 社会健康医学系専攻 健康増進・行動学分野


From the Professor

Professor : Toshiaki A. Furukawa, MD, PhD

Kyoto University was founded in 1897 as the second imperial university in Japan. It now hosts 10 undergraduate faculties, 17 graduate schools and 31 research institutes. Kyoto University is one of the top research universities not only in Japan or Asia but in the world. It is ranked the 26th, 38th or 88th(49th, 49th and 53rd in the field of medicine) according to the most recent world university rankings by AWRU, QS and THE respectively . It boasts of nine Nobel laureates and two Fields medalists among its alumni and faculty.

Kyoto University School of Public Health (KUSPH) was inaugurated on this fertile ground in 2000 as the first graduate school of public health in Japan. It forms part of the Graduate School of Medicine and is the only school of public health in this country that can award both degrees of Master of Public Health and Doctor of Public Health. Being part of the larger Kyoto University Graduate School of Medicine, we can also award Doctor of Philosophy (PhD) in Medicine.

Department of Health Promotion and Human Behavior is one of the 17 departments within this KUSPH. I became professor and chair of this department in July 2010. As can be seen from my brief CV below, my background is psychiatry and cognitive-behavior therapy, with especial interest in clinical epidemiology and evidence-based medicine.

I had been professor and chair of a clinical department of psychiatry at Nagoya City University for over 10 years before I moved to KUSPH. There I was blessed with clinically competent and enthusiastic colleagues and residents and I took immense pleasure in training young psychiatrists-to-be. Not only did I endeavor to foster in them appropriate skills and attitudes to practice clinical psychiatry but also to base these competences on sound evidence-based critical thinking and knowledge. We were also gradually starting to create clinical evidence in addition to using it.

After 10 years and after having done all I can to achieve these goals at Nagoya City University, however, it was perhaps time for me to move on and take on new challenges. I had always thought that I, as medical doctor, can serve humankind in four ways: 1) to see patients myself, 2) to train doctors to see patients, 3) to build evidence base to be used in such processes, and 4) to regulate resource allocations so that all #1 through #3 can be maximized. Before becoming professor, I was doing a lot of #1 and some of #3. After becoming department chair, I was doing a little bit of #1, a lot of #2 and some #3. Now it is time for me to do #2 for many more psychiatrists and other mental health professionals across Japan and more of #3 for mental and behavioral problems in the world. KUSPH Department of Health Promotion and Human Behavior appears to offer me such a chance and I would like to meet this challenge.

Professor : Toshiaki A. Furukawa, MD, PhD

Professor Toshiaki A. Furukawa's CV

List of postgraduate training, professional and academic appointments

October 1958 Born in Kyoto, Japan
May 1976 Graduated from Clayton High School, St. Louis, Missouri, USA
September 1981 - June 1982 Studied one year in the Department of Psychology, School of Human Sciences, Université de Poitiers, Poitiers, France
March 1985 Received the degree of Doctor of Medicine and graduated from the School of Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan
May 1985 Received the Physician's License under the provisions of the Medical Practitioners Law of Japan
May 1985 - March 1987 Clinical training fellow in psychiatry in the Department of Psychiatry, Nagoya City University Hospital, Nagoya, Japan
April 1987 - March 1992 Staff psychiatrist in the Department of Psychiatry, Toyohashi Municipal Hospital, Toyohashi, Japan
April 1992 - March 1993 Clinical research fellow in the Department of Psychiatry, Nagoya City University Hospital, Nagoya, Japan
April 1993 - March 1994 Staff psychiatrist at Minamichita Hospital, Aichi, Japan
April 1994 - March 1995 Clinical research fellow in the Department of Psychiatry, Nagoya City University Hospital, Nagoya, Japan
July 1994 Received the degree of Doctor of Philosophy (Medical Sciences) from Nagoya City University Medical School, Nagoya, Japan
October 1994 Qualified as Designated Physician of Mental Health from the Ministry of Health and Welfare under the provisions of the Mental Health Law
April 1995 - December 1996 Assistant professor in the Department of Psychiatry, Nagoya City University Medical School, Nagoya, Japan
Jan 1997 - May 1998 Junior lecturer in the Department of Psychiatry, Nagoya City University Medical School, Nagoya, Japan
June 1997 - November 1997 Visiting Professor in the Department of Psychiatry, McMaster University, Hamilton, Canada
June 1998 - August 1999 Lecturer in the Department of Psychiatry, Nagoya City University Medical School, Nagoya, Japan
September 1999 - March 2002 Professor and Chair of the Department of Psychiatry, Nagoya City University Medical School, Nagoya, Japan
April 2002 - June 2010 Professor and Chair of the Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
July 2010 - Professor and Chair of the Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan


  • Academy of Cognitive Therapy (Diplomate)
  • American Psychiatric Association (International Member)
  • Collegium Internationale Neuro-Psychopharmacologicum (Fellow)
  • International Society of Affective Disorders (Fellow)
  • Association for Behavioral and Cognitive Therapies (Member)
  • Japanese Society of Psychiatry and Neurology (Member)
  • Japan Psycho-Oncology Society (Board of Directors)
  • Japanese Society of Cognitive Therapy (Board of Directors)
  • Japanese Society of Clinical Psychoneuropharmacology (Board of Trustees)
  • Japanese Society of Mood Disorders (Board of Trustees)
  • Editor, Cochrane Collaboration Depression, Anxiety and Neurosis Group
  • Deputy Editor, Evidence-Based Mental Health
  • Advisory Editor, Lancet Psychiatry
  • Advisory Editor, Psychiatry and Clinical Neurosciences
  • Advisory Board, Trials

List of major publications in English

Mood disorders
  • Furukawa, T. A., Kitamura, T. & Takahashi, K. (2000). Time to recovery of an inception cohort of hitherto untreated unipolar major depressive episodes. British Journal of Psychiatry 177, 331-335.
  • Kanai T, Takeuchi H, Furukawa TA, Yoshimura R, Imaizumi T, Kitamura T & Takahashi K (2003) Time to recurrence after recovery from major depressive episodes and its predictors. Psychological Medicine, 33, 839-845.
  • Furukawa TA, Yoshimura R, Harai H, Imaizumi T, Takeuchi H, Kitamura T & Takahashi K (2009) How many well vs. unwell days can you expect over 10 years, once you become depressed? Acta Psychiatrica Scandinavica, 119, 290-297.
  • Kato T, Furukawa TA, Mantani A, Kurata K, Kubouchi H, Hirota S, Sato H, Sugishita K, Chino B, Itoh K, Ikeda Y, Shinagawa Y, Kondo M, Okamoto Y, Fujita H, Suga M, Yasumoto S, Tsujino N, Inoue T, Fujise N, Akechi T, Yamada M, Shimodera S, Watanabe N, Inagaki M, Miki K, Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Shinohara K, Yonemoto N, Tanaka S, Zhou Q, Guyatt GH & for the SUN(^_^)D Investigators (2018) Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Medicine, 16, 103.
  • Furukawa TA, Cipriani A, Atkinson LZ, Leucht S, Ogawa Y, Takeshima N, Hayasaka Y, Chaimani A & Salanti G (2016) Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry, 3, 1059-1066.
  • Schramm E, Klein DN, Elsaesser M, Furukawa TA & Domschke K (2020) Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. Lancet Psychiatry, 7, 801-812.
Cognitive-behavior therapy
  • Furukawa TA, Chen J, Watanabe N, Nakano Y, Ietsugu T, Ogawa S, Funayama T & Noda Y (2009) Videotaped experiments to drop safety behaviors and self-focused attention for patients with social anxiety disorder: Do they change subjective and objective evaluations of anxiety and performance? Journal of Behavior Therapy and Experimental Psychiatry, 40, 202-210.
  • Watanabe N, Furukawa TA, Shimodera S, Morokuma I, Katsuki F, Fujita H, Sasaki M, Kawamura C & Perlis ML (2011) Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial. Journal of Clinical Psychiatry, 72, 1651-1658.
  • Furukawa TA, Horikoshi M, Kawakami N, Kadota M, Sasaki M, Sekiya Y, Hosogoshi H, Kashimura M, Asano K, Terashima H, Iwasa K, Nagasaku M, Grothaus LC & on behalf of the GENKI Project (2012) Telephone cognitive-behavioral therapy for subthreshold depression and presenteeism in workplace: a randomized controlled trial. PLoS ONE, 7, e35330.
  • Furukawa TA, Noma H, Caldwell DM, Honyashiki M, Shinohara K, Imai H, Chen P, Hunot V & Churchill R (2014) Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatrica Scandinavica, 130, 181-192.
  • Furukawa TA, Weitz ES, Tanaka S, Hollon SD, Hofmann SG, Andersson G, Twisk J, DeRubeis RJ, Dimidjian S, Hegerl U, Mergl R, Jarrett RB, Vittengl JR, Watanabe N & Cuijpers P (2017) Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data meta-analysis of pill-placebo-controlled trials. British Journal of Psychiatry, 210, 190-196.
  • Mantani A, Kato T, Furukawa TA, Horikoshi M, Imai H, Hiroe T, Chino B, Funayama T, Yonemoto N, Zhou Q & Kawanishi N (2017) Smartphone Cognitive Behavioral Therapy as an Adjunct to Pharmacotherapy for Refractory Depression: Randomized Controlled Trial. Journal of Medical Internet Research, 19, e373.
  • Furukawa TA, Efthimiou O, Weitz ES, Cipriani A, Keller MB, Kocsis JH, Klein DN, Michalak J, Salanti G, Cuijpers P & Schramm E (2018) Cognitive-Behavioral Analysis System of Psychotherapy, drug, or their combination for persistent depressive disorder: Personalizing the treatment choice using individual participant data network metaregression. Psychotherapy and Psychosomatics, 87, 140-153.
  • Cuijpers P, Noma H, Karyotaki E, Cipriani A & Furukawa TA (2019) Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: A network meta-analysis. JAMA Psychiatry, 76, 700-707.
  • Karyotaki E, Efthimiou O, Miguel C, Maas F, Furukawa TA, Cuijpers P & for the Individual Patient Data Meta-analysis for Depression (IPDMA-DE) Collaboration (in press) Internet-based cognitive behavioral therapy for depression: An individual patient data network meta-analysis. JAMA Psychiatry.
  • Furukawa TA, Suganuma A, Ostinelli EG, Andersson G, Beevers CG, Shumake J, Berger T, Boele FW, Buntrock C, Carlbring P, Choi I, Christensen H, Mackinnon A, Dahne J, Huibers MJH, Ebert DD, Farrer L, Forand NR, Strunk DR, Ezawa ID, Forsell E, Kaldo V, Geraedts A, Gilbody S, Littlewood E, Brabyn S, Hadjistavropoulos HD, Schneider LH, Johansson R, Kenter R, Kivi M, Björkelund C, Kleiboer A, Riper H, Klein JP, Schröder J, Meyer B, Moritz S, Bücker L, Lintvedt O, Johansson P, Lundgren J, Milgrom J, Gemmill AW, Mohr DC, Montero-Marin J, Garcia-Campayo J, Nobis S, Zarski AC, O'Moore K, Williams AD, Newby JM, Perini S, Phillips R, Schneider J, Pots W, Pugh NE, Richards D, Rosso IM, Rauch SL, Sheeber LB, Smith J, Spek V, Pop VJ, Ünlü B, van Bastelaar KMP, van Luenen S, Garnefski N, Kraaij V, Vernmark K, Warmerdam L, van Straten A, Zagorscak P, Knaevelsrud C, Heinrich M, Miguel C, Cipriani A, Efthimiou O, Karyotaki E & Cuijpers P (in press) Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data. Lancet Psychiatry.
Systematic reviews
  • Furukawa, T. A., McGuire, H., Barbui, C. (2002) Meta-analysis of effects and side-effects of low dosage tricyclic antidepressants for depression: systematic review. BMJ 325: 991-995.
  • Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E. & Goodwin, G. M. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders. Lancet 361: 653-661.
  • Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., Tansella, M. & Barbui, C. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet, 373, 746-758.
  • Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O & Salanti G (2016) Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 4, CD011004.
  • Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, Motomura K, Shimano-Katsuki S, Leucht S, Cipriani A, Geddes JR & Kanba S (2014) Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: A network meta-analysis. Lancet Psychiatry, 1, 351-359.
  • Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA & Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 391, 1357-1366.
  • Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M & Salanti G (2019) Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry, 6, 601-609.
  • Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR & Cipriani A (2021) Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry, 78, 141-150.
Theoretical works in clinical epidemiology
  • Furukawa, T., Goldberg, D.P. (1999) Cultural invariance of likelihood ratios for the General Health Questionnaire. Lancet 353, 561-562
  • Furukawa, T.A. (1999) From effect size into number needed to treat. Lancet 353, 1680
  • Furukawa, T. A., Guyatt, G. H. & Grifitth, L. E. (2002). Can we individualize the Number Needed to Treat (NNT)? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 31: 72-76.
  • Furukawa, T. A., Watanabe, N., Omori, I. M., Montori, V. M. & Guyatt, G. H. (2007) Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA, 297, 468-470.
  • Furukawa TA & Guyatt G (2014) An illustration of bias and random error. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice (3rd edn). (eds Guyatt G, Rennie D, Meade MO & Cook DJ), pp. 103-106. New York: The McGraw-Hill Companies, Inc.
  • Furukawa TA, Scott I & Guyatt G (2014) Measuring patients' experience. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice (3rd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 219-234. New York: The McGraw-Hill Companies, Inc.
  • Furukawa TA, Strauss S, Bucher HC, Agoritsas T & Guyatt G (2014) Diagnostic tests. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Practice (3rd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 345-358. New York: The McGraw-Hill Companies, Inc.
  • Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A & Leucht S (2015) Initial severity of schizophrenia and efficacy of antipsychotics: Participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry, 72, 14-21.
  • Tajika A, Ogawa Y, Takeshima N, Hayasaka Y & Furukawa TA (2015) Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up. British Journal of Psychiatry, 207, 357-362.
  • Nikolakopoulou A, Mavridis D, Furukawa TA, Cipriani A, Tricco AC, Straus SE, Siontis GCM, Egger M & Salanti G (2018) Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study. BMJ, 360, k585.
  • Devji T, Carrasco-Labra A, Qasim A, Phillips M, Johnston BC, Devasenapathy N, Zeraatkar D, Bhatt M, Jin X, Brignardello-Petersen R, Urquhart O, Foroutan F, Schandelmaier S, Pardo-Hernandez H, Vernooij RW, Huang H, Rizwan Y, Siemieniuk R, Lytvyn L, Patrick DL, Ebrahim S, Furukawa T, Nesrallah G, Schunemann HJ, Bhandari M, Thabane L & Guyatt GH (2020) Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. BMJ, 369, m1714.
  • Maslej MM, Furukawa TA, Cipriani A, Andrews PW, Sanches M, Tomlinson A, Volkmann C, McCutcheon RA, Howes O, Guo X & Mulsant BH (2021) Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. JAMA Psychiatry, 78, 490-497.
Copyright© 2010-22 Health Promotion and Human Behavior, Kyoto University. All Rights Reserved.
Top of Page